Renalytix plc announced the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical group, to help advance the use of FDA authorized kidneyintelX.dkd? in mitigating uncontrolled kidney disease progression and guiding early stage treatment strategies for the estimated 14 million Americans with diabetic kidney disease. The Clinical Advisory Board members include: Stephen Brunton, MD, FAAFP, CDCES; University of North Carolina, Executive Director of Primary Care Metabolic Group (PCMG) and Editor-in-Chief of Clinical Diabetes Matthew Jay Budoff, MD, FACC, FAHA; David Geffen School of Medicine at UCLA and Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center Barry I. Freedman, MD, FACP; John Felts Distinguished Professor and Chief of the Nephrology Section at Wake Forest University School of Medicine Ralph A. DeFronzo, MD; Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute Holly J. Mattix-Kramer MD, MPH; Division of Nephrology and Hypertension at Loyola University Chicago, Associate Director of Research for the Medicine Service Line and Founding Director of the Hines VA Serwa Research Center on Aging Javier Morales MD, FACP, FACE; Vice President and Principal Clinical Trials Investigator at Advanced Internal Medicine Group Joseph A. Vassalotti MD; Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor of Medicine in the Division of Nephrology at Icahn School of Medicine at Mount Sinai Eugene E. Wright Jr., MD; Duke University Medical Center and Medical Director for Performance Improvement at the Charlotte Area Health Education Center.